Abstract
Calcineurin (protein phosphatase 3, Cn) is best known for its central position in Ca2+-dependent T-cell signaling. Interest in calcineurin has, however, conserved its momentum as new Ca2+-dependent pathways have been steadily surfacing in several other cell types, such as brain, heart, skin cells and beta pancreatic cells, and Cn appears to serve as a central controller of stress, immune response, and cellular proliferation and differentiation. Calcineurin is the principal target of the immunosuppressive drugs cyclosporin A (CsA) and tacrolimus (TRL). Therapy based on these immunosuppressants has markedly reduced the incidence of transplant rejection in allograft recipients. In addition, these drugs have proven very useful for patients suffering from chronic inflammatory skin conditions. Unfortunately, their application is somewhat limited by a broad spectrum of toxic side-effects, affecting several organ systems. This calls for enhancements in the design of this class of immunosuppressants. An intricate constellation of regulatory systems allows for precise modulation and adaptation of calcineurin activity in vivo. The last few years have been very fruitful in elucidating several long-standing issues regarding the binding patterns of substrates and inhibitors to Cn. This new knowledge may enable more precise manipulation of the Ca2+-calcineurin pathway in the near future, preferably targeted towards one specific substrate or cell system. In this review, we will discuss the factors and mechanisms underlying calcineurin activity regulation and their exploitation in recent approaches towards better immunosuppressants.
Keywords: Calcineurin, immunosuppressants, NFAT, RCAN, cyclosporin A (CsA), tacrolimus (TRL), CaM-binding domain, calpain, cardiomyocytes, Cn phosphatase activity, tacrolimus, phobic CnA, immunophilin, immunophilin complexes, inositol 1,4,5-triphosphate (IP3), Cyclosporin A, pimecrolimus, lipophilicity, topology, metalloenzyme, bovine brain, glycemic control, thioredoxin, phospholipids, arachidonic acid, polyphenolic aldehyde gossypol, protein phosphatase
Current Medicinal Chemistry
Title: Regulatory Mechanisms of Calcineurin Phosphatase Activity
Volume: 18 Issue: 2
Author(s): R. E.A. Musson and N. P.M. Smit
Affiliation:
Keywords: Calcineurin, immunosuppressants, NFAT, RCAN, cyclosporin A (CsA), tacrolimus (TRL), CaM-binding domain, calpain, cardiomyocytes, Cn phosphatase activity, tacrolimus, phobic CnA, immunophilin, immunophilin complexes, inositol 1,4,5-triphosphate (IP3), Cyclosporin A, pimecrolimus, lipophilicity, topology, metalloenzyme, bovine brain, glycemic control, thioredoxin, phospholipids, arachidonic acid, polyphenolic aldehyde gossypol, protein phosphatase
Abstract: Calcineurin (protein phosphatase 3, Cn) is best known for its central position in Ca2+-dependent T-cell signaling. Interest in calcineurin has, however, conserved its momentum as new Ca2+-dependent pathways have been steadily surfacing in several other cell types, such as brain, heart, skin cells and beta pancreatic cells, and Cn appears to serve as a central controller of stress, immune response, and cellular proliferation and differentiation. Calcineurin is the principal target of the immunosuppressive drugs cyclosporin A (CsA) and tacrolimus (TRL). Therapy based on these immunosuppressants has markedly reduced the incidence of transplant rejection in allograft recipients. In addition, these drugs have proven very useful for patients suffering from chronic inflammatory skin conditions. Unfortunately, their application is somewhat limited by a broad spectrum of toxic side-effects, affecting several organ systems. This calls for enhancements in the design of this class of immunosuppressants. An intricate constellation of regulatory systems allows for precise modulation and adaptation of calcineurin activity in vivo. The last few years have been very fruitful in elucidating several long-standing issues regarding the binding patterns of substrates and inhibitors to Cn. This new knowledge may enable more precise manipulation of the Ca2+-calcineurin pathway in the near future, preferably targeted towards one specific substrate or cell system. In this review, we will discuss the factors and mechanisms underlying calcineurin activity regulation and their exploitation in recent approaches towards better immunosuppressants.
Export Options
About this article
Cite this article as:
E.A. Musson R. and P.M. Smit N., Regulatory Mechanisms of Calcineurin Phosphatase Activity, Current Medicinal Chemistry 2011; 18 (2) . https://dx.doi.org/10.2174/092986711794088407
DOI https://dx.doi.org/10.2174/092986711794088407 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Transition of Care for Patients with Diabetes
Current Diabetes Reviews Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology The Role of Nitro (NO<sub>2</sub>-), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds
Current Drug Targets Endogenous Cardiotonics: Search and Problems
Cardiovascular & Hematological Disorders-Drug Targets LCHAD and MTP Deficiencies - Two Disorders of Mitochondrial Fatty Acid β-Oxidation with Unusual Features
Current Pediatric Reviews Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention
Current Drug Targets Chaperones and Cardiac Misfolding Protein Diseases
Current Protein & Peptide Science Levosimendan Preoperative
Current Pharmaceutical Design Ca2+ Fluxes Involvement in Gene Expression During Cardiac Hypertrophy
Current Vascular Pharmacology Revised Genetic Classification of Limb Girdle Muscular Dystrophies
Current Molecular Medicine Potential Therapeutic Effect of Antioxidant Therapy in Shock and Inflammation
Current Medicinal Chemistry Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry What is Tobacco Smoke? Sociocultural Dimensions of the Association with Cardiovascular Risk
Current Pharmaceutical Design Evaluation of the Pulmonary Veins and Left Atrial Volume using Multidetector Computed Tomography in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Current Cardiology Reviews